SEARCH

SEARCH BY CITATION

References

  • 1
    Reed E, Kohn KW. Cisplatin and platinum analogues. In: Chabner BA, Collins JM, editors. Cancer chemotherapy: principles and practice. Philadelphia: JB Lippincott, 1990: 46590.
  • 2
    Litterst CL, Reed E. Platinum compounds. In: Kaiser HE, editor. Progressive stages of malignant neoplastic growth. London: Alden Press, 1989: 8597.
  • 3
    Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 146471.
  • 4
    Muggia FM. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989; 16 Suppl 5: 713.
  • 5
    Harrap KR. Platinum analogues: criteria for selection in cancer chemotherapy I. In: Muggia FM, editor. Cancer treatment and research series. Boston: Martinus Nijhoff, 1983: 172217.
  • 6
    Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12 Suppl A: 2133.
  • 7
    Rose WC, Schurig JE. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 1985; 12 Suppl A: 119.
  • 8
    Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev 1985; 12 Suppl A: 6771.
  • 9
    Reed E. Cisplatin. In: Pinedo HM, Chabner BA, Longo DL, editors. Cancer chemotherapy and biological response modifiers. vol. 11. Amsterdam: Elsevier Science Publishers, 1990: 906.
  • 10
    Levin L, Hyrniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 75667.
  • 11
    Ozols RF, Ostchega Y, Myers CE, Young RC. Cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 124650.
  • 12
    Ozols RF, Ostchega Y, Curt G, Young RC. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987; 5: 197201.
  • 13
    Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986; 154: 63947.
  • 14
    Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R, Baratier F. High dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 1979; 3: 18996.
  • 15
    Hansen HH, Selawry OS, Holland JF, McCall CB. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971; 25: 298305.
  • 16
    Hrushesky WJM, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76: 57984.
  • 17
    Rothenberg ML, Ostchega Y, Steinberg SM, Young RC, Hummel S, Ozols RF. High dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 1988; 80: 148892.
  • 18
    Reed E, Janik J, Bookman M, Rothenberg M, Smith J II, Ozols RF, et al. High dose carboplatin (HD-C) with rGM-CSF (GM) in refractory ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1990; 9: 157.
  • 19
    Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 7684.
  • 20
    Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the eastern cooperative oncology group. Cancer 1983; 52: 198692.
  • 21
    Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989; 16: 6675.